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Purpose: We determined the efficacy and safety of a
relatively high dose of terazosin (5 mg) in Korean patients
with lower urinary tract symptoms (LUTS), with or without
concomitant hypertension. Materials and Methods: From July
to December 2006, 200 men who consecutively presented with
LUTS were prospectively studied. Eight weeks after treatment,
blood pressure (BP), uroflowmetry, and International Prostate
Symptom Score (I-PSS) were assessed. For analysis purposes,
patients were stratified according to concomitant hypertension.
Of the 200 patients, 173 completed the scheduled eight-week
treatment period. Results: At baseline, no differences were
evident in the two groups in terms of I-PSS, Qmax, PVR and
BP. After eight weeks of treatment-although I-PSS and uro-
flowmetry parameters were not significantly different in the
two groups-systolic and diastolic BP in the non-hypertensive
control group were higher than in the hypertensive group (p=
0.001 and p = 0.0100, respectively). Changes in I-PSS, uro-
flowmetry parameters, and BPs measured at week eight post-
treatment commencement did not significantly differ between
the two groups. Moreover, the addition of 5 mg of terazosin
to antihypertensives did not cause a significant reduction in
either systolic or diastolic BP in either group. Conclusion:
Adding terazosin to existing antihypertensive regimens did not
seem to increase the incidence of adverse events. Our findings
suggest that 5 mg terazosin is effective and that it has an
acceptable safety profile as an add-on therapy for patients with
LUTS and concomitant hypertension.
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INTRODUCTION
Benign prostatic hyperplasia (BPH) is often
encountered in aging men with, usually, one or
more co-morbidities. BPH and hypertension occur
concomitantly in an estimated 25% of men aged
60 years and older.
1 In addition to their frequent
coexistence, BPH and hypertension may have a
common etiology in the sympathetic nervous
system. Alpha1-adrenoceptor antagonists are the
most commonly used first-line drugs for the
management of symptomatic BPH. However,
alpha1-adrenoceptor antagonists are not first-line
therapies for hypertension, and the majority of
hypertensive BPH patients will be receiving other
antihypertensive agents that may increase the risk
of drug interactions and side-effects. In addition,
hypertension may reduce the effect of an alpha1-
adrenoceptor antagonist on lower urinary tract
symptoms (LUTS).
2 Furthermore, although 5 or 10
mg terazosin daily been routinely used in North
America and Europe, terazosin is equally effective
for treating symptomatic BPH in Asian patients at
lower doses than those used in the West.
3-5 In the
present study, we sought to determine the efficacy
and safety of a relatively high dose of terazosin
(5 mg) in Korean patients with LUTS, with or
without concomitant hypertension.
MATERIALS AND METHODS
From July to December 2006, 200 men who
presented consecutively with LUTS and who were
eligible and willing to participate in this study
High-Dose Terazosin Therapy (5 mg) in Korean Patients with
Lower Urinary Tract Symptoms with or without Concomitant
Hypertension: A Prospective, Open-Label Study
Cheol Kwak,
1 Jeong Ki Lee,
2 and Ja Hyeon Ku
1
1Department of Urology, Seoul National University College of Medicine, and
2Seoul Veterans Hospital, Seoul, Korea.
Received March 6, 2007
Accepted May 3, 2007
This study was supported by the Ilyang Pharmaceuticals Co.,
Ltd., Korea.
Reprint address: requests to Dr. Ja Hyeon Ku, Department of
Urology, Seoul National University College of Medicine, 28 Yongon-
dong, Jongno-gu, Seoul 110-744, Korea. Tel: 82-2-2072-0361, Fax:
82-2-742-4665, E-mail: randyku@hanmail.netTerazosin Therapy and Hypertension
Yonsei Med J Vol. 48, No. 6, 2007
were prospectively studied. Before inclusion in
this study, all patients provided written informed
consent. The Institutional Review Board of our
hospital approved the protocol. The study inclusion
criteria were as follows: age of at least 45 years,
moderate to severe LUTS [International Prostate
Symptom Score (I-PSS) 8], and a reduced
maximum flow rate (Qmax; 15 mL/sec). Exclu-
sion criteria included a recent history of cardio-
vascular or cerebrovascular disease, hypotension
or a history of fainting spells, restricted mobility,
bladder cancer, prostate cancer, neurogenic
bladder dysfunction, urinary stones, urethral
strictures, acute or chronic urethritis, urinary tract
history of bladder or prostate surgery or radio-
therapy, acute urinary retention, or an indwelling
catheter. Patients were also excluded from the
analysis if they had a documented history of
prostatic intraepithelial neoplasia by biopsy or a
serum prostate-specific antigen (PSA) level in
excess of 20 ng/mL. Concomitant administration
of diuretics, angiotensin-converting enzyme
inhibitors, beta-blockers, and/or calcium channel
blockers was allowed, but verapamil, alpha-
adrenergic antagonists, alpha-agonists, antiandrogen
therapy, anticholinergic agents, or androgens
were not allowed.
Patients were evaluated with respect to the
following: detailed medical history, physical ex-
amination, blood pressure (BP), urinalysis, serum
PSA, transrectal ultrasonography, uroflowmetry,
post-voiding residual (PVR) urine volume by
bladder scanning (BVI-3000, Diagnostic Ultrasound
Co., Redmond, WA, USA), and I-PSS evaluation.
Histories regarding concomitant diseases and all
current medications were obtained from each
patient. Terazosin was initiated at a dose of 1 mg
once daily for the first seven days, 2 mg once
daily for the next seven days, and 5 mg once daily
for the following six weeks. After treatment, BP,
uroflowmetry, PVR, and I-PSS were assessed.
The primary outcome of efficacy (symptom
severity) was determined base on changes in
LUTS. Baseline symptom severity and treatment
efficacy were determined using I-PSS. Changes in
Qmax, PVR, and BP were used as secondary out-
comes of efficacy. Potentially important changes
in BP were analyzed by counting the number of
subjects (outliers) with a supine systolic BP of <
85 mm Hg and a diastolic BP of < 45 mm Hg, and
subjects with a decrease in supine systolic BP of
> 30 mm Hg or in diastolic BP of > 20 mm Hg.
These changes in BP were considered clinically
important because they represent changes expected
to produce hypotensive symptoms including
dizziness, flushing, or syncope in some patients.
6
Adverse events were captured at eight weeks (at
the end of the study) via interview. Safety was
analyzed on an intent-to-treat (ITT) basis on
subjects who took the study drug at least once
and who were assessed for relevant variables at
least once.
For analysis purposes, patients were stratified
according to concomitant hypertension. Survey
responses were coded and analyzed using
descriptive statistics. All values are expressed as
medians (5 - 95th percentiles) or numbers (%). The
two groups were compared with respect to
medians of each domain using the Mann-Whitney
U-test or the Kruskal-Wallis test. Categorical
variables were compared using the Fisher's exact
test. The Wilcoxon signed-rank test was used to
compare values before and after treatment in each
group. A 5% level of significance was used for all
statistical testing, and statistical analyses were
performed using a commercially available analysis
program, SPSS (SPSS Inc., Chicago, IL, USA).
RESULTS
Of the 200 patients, 190 patients received treat-
ment, including 111 in the non-hypertensive
control group and 79 in the hypertensive group.
Of the 190 treated patients, 173 completed the
eight weeks of treatment. Patient clinical charac-
teristics were comparable in the two groups
(Table 1). Baseline and post-treatment clinical
parameters are shown in Table 2. At baseline, no
differences were evident in the two groups with
respect to I-PSS, Qmax, PVR, and BP. After eight
weeks of treatment, I-PSS and uroflowmetry
parameters and BP were not significantly different
in the two groups. Terazosin treatment was asso-
ciated with a significant improvement in subjective
symptoms and most objective parameters in both
groups. However, values of PVR and BVE did not
change with treatment in either group, andCheol Kwak, et al.
Yonsei Med J Vol. 48, No. 6, 2007
changes in I-PSS, uroflowmetry parameters, and
BP due to treatment were not significantly dif-
ferent between the groups (Table 3). Changes in
BP according to the class of concomitant an-
tihypertensives received are shown in Table 4. The
addition of 5 mg terazosin to antihypertensives
did not cause a significant reduction in either sys-
tolic or diastolic BP in either group, and adding
terazosin to existing antihypertensive regimens
did not increase the incidence of adverse events.
The incidences of withdrawal because of adverse
events were 0% in the hypertensive group and
2.7% in the control group (Table 5).
DISCUSSION
To the best to our knowledge, this is the first
study to evaluate the safety and effectiveness of
5 mg terazosin in Korean men with LUTS, with or
without concomitant hypertension. Two of the
results obtained are of note. First, in the present
Table 2. Data at Baseline and Post-Treatment
Baseline After treatment p*
International Prostate Symptom Score (item no.)
Total sum (1 - 7) 23.0 (18.0 - 27.0) 14.0 (9.0 - 19.5) < 0.001
Voiding symptoms (1,3,5,6) 13.0 (10.0 - 16.0) 9.0 (5.0 - 12.5) < 0.001
Storage symptoms (2,4,7) 9.0 (6.5 - 11.0) 5.0 (3.0 - 7.0) < 0.001
Quality of life index 5.0 (4.0 - 6.0) 3.0 (2.5 - 4.0) < 0.001
Uroflowmetry
Maximum flow rate (mL/s) 11.0 (9.0 - 13.0) 16.0 (14.0 - 19.0) < 0.001
Post-void residual (mL) 10.0 (0.0 - 30.0) 10.0 (0.0 - 30.0) 0.538
Bladder voiding efficiency (%) 94.5 (88.6 - 100.0) 95.6 (90.1 - 100.0) 0.152
Blood pressure
Systolic (mmHg) 133.0 (125.0 - 143.0) 129.0 (119.5 - 138.0) < 0.001
Diastolic (mmHg) 79.0 (70.5 - 83.0) 72.0 (65.5 - 77.0) < 0.001
*Wilcoxon signed rank test.
Data presented are medians (5th-95th percentiles).
Table 1. Patients’ Clinical Characteristics
Control group Hypertensive group p*
No. 102 71
Age (yrs) 61.5 (56.3 - 75.2) 62.2 (55.7 - 75.2) 0.845
Symptom duration (months) 13.0 (2.0 - 74.6) 12.0 (1.0 - 105.6) 0.599
Serum prostate-specific antigen (ng/mL) 1.04 (0.37 - 4.33) 1.01 (0.25 - 3.53) 0.795
Total prostate volume (mL) 21.6 (14.1 - 38.9) 23.7 (13.3 - 43.1) 0.216
Transition zone volume (mL) 7.4 (4.2 - 17.1) 7.9 (3.6 - 25.5) 0.163
Transition zone index 0.34 (0.21 - 0.53) 0.36 (0.20 - 0.60) 0.549
*Mann Whitney U-test.
Data presented are medians (5th-95th percentiles).Terazosin Therapy and Hypertension
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study, 5 mg terazosin was found to be safe in
Korean men with LUTS with or without hyper-
tension, and second, subjective and objective
parameters improved in both the hypertensive
and the non-hypertensive control groups.
Optimal alpha-blocker doses vary by race,
constitution, and socio-economic status. Lepor et
al.
6 reported that 2 mg terazosin daily did not
improve obstructive or irritative symptoms as
compared with placebo. However, a placebo-
controlled double-blind study in Japan showed
that a four-week treatment with 2 mg terazosin
daily improved subjective symptoms.
7 Lee and
Lee
5 found that 0.2 mg tamsulosin was better than
1 - 5 mg terazosin, because although no difference
in efficacy was found between them a more favor-
able adverse reaction profile was found for
tamsulosin. Okada et al.
4 reported that reducing
terazosin to 1 - 2 mg daily caused adverse reac-
tions to fall to minimal levels, and that terazosin
appeared to be as well-tolerated as tamsulosin.
These findings suggest that careful studies on
alpha-blockers are required to establish ideal
therapeutic strategies for symptomatic BPH on a
country-by-country basis, and are needed to
establish differences between therapeutic agents
for the treatment of BPH.
A previous study showed that hypertensive
BPH patients have more severe LUTS than nor-
motensive BPH patients, and that hypertension
worsens LUTS and may reduce the efficacy of
terazosin.
2 However, in the present study, clinical
parameters at baseline were similar in the two
study groups. In addition, I-PSS and uroflo-
wmetry parameters improved in both groups after
terazosin administration, and the two groups
were similar with respect to these parameters. In
the present study, patients were given 1 mg
terazosin once daily for the first week, 2 mg once
daily for the second week, and 5 mg once daily for
the following six weeks. Nakamura et al.
8
investigated the effect of terazosin at 2 mg/day
for one week on Qmax, and reported a significant
improvement after only two days of treatment.
Thus, the dose of terazosin appears to be lower,
and the duration of treatment necessary to achieve
Table 3. Differences Attributed to Treatment
Control group Hypertensive group p*
No. 102 71
International Prostate Symptom Score (item no.)
Total sum (1 - 7) - 8.0 (- 16.9, 0.0) - 7.0 (- 19.0, 1.0) 0.313
Voiding symptoms (1,3,5,6) - 5.0 (- 10.9, 2.0) - 4.0 (- 12.0, 2.0) 0.339
Storage symptoms (2,4,7) - 4.0 (- 7.9, 1.0) - 3.0 (- 8.0, 1.4) 0.432
Quality of life index - 2.0 (- 3.0, 0.0) - 2.0 (- 3.0, 0.0) 0.980
Uroflowmetry
Maximum flow rate (mL/s) 6.0 (0.0, 11.9) 5.0 (0.0, 16.0) 0.730
Post-void residual (mL) 0.0 (- 64.3, 49.0) 0.0 (- 91.6, 73.2) 0.444
Bladder voiding efficiency (%) 0.0 (- 18.1, 18.3) 0.0 (- 18.6, 22.1) 0.135
Blood pressure
Systolic (mmHg) - 6.0 (-3 0.0, 14.9) - 4.0 (- 20.6, 24.0) 0.109
Diastolic (mmHg) - 6.0 (- 20.0, 4.9) - 4.0 (- 19.4, 14.4) 0.124
Potentially clinically important changes 3 (2.9%) 2 (2.8%) 1.000
*Mann Whitney U-test.
Fisher’s exact test.
Data presented are medians (5th-95th percentiles).Table 5. Adverse Effects
Control group (%) Hypertensive group (%)
No. 111 79
Dizziness 13 (11.7%) 7 (8.9%)
Postural hypotension 5 (4.5%) 5 (6.3%)
Asthenia/fatigue 1 (0.9%) 0 (0.0%)
Syncope 1 (0.9%) 0 (0.0%)
Blurred vision 1 (0.9%) 0 (0.0%)
Edema 1 (0.9%) 0 (0.0%)
Gastrointestinal disorders 2 (1.8%) 1 (1.3%)
Discontinued due to adverse events 3 (2.7%) 0 (0.0%)
Data presented are numbers (%).
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Table 4. Baseline and Post-Treatment Values, and Difference between the Two for Blood Pressures in
Hypertensive Patients
No. Baseline Post-treatment Difference p*
Systolic BP (mmHg)
Diuretics 18 140.0 (112.0 - 164.0) 133.5 (109.0 - 157.0) - 6.0 (- 24.0, 22.0) 0.127
ACE inhibitors 3 140.0 (137.0 - 180.0) 140.0 (125.0 - 168.0) - 12.0 (- 15.0, 3.0) 0.285
Beta-blockers 11 133.0 (108.0 - 161.0) 130.0 (110.0 - 170.0) - 2.0 (- 31.0, 16.0) 0.755
Calcium antagonist 19 132.0 (100.0 - 168.0) 133.0 (112.0 - 176.0) - 2.0 (- 23.0, 32.0) 0.948
Combination A 13 131.0 (120.0 - 170.0) 130.0 (107.0 - 156.0) - 6.0 (- 17.0, 24.0) 0.346
Combination B
§ 7 136.0 (108.0 - 149.0) 133.0 (110.0 - 145.0) - 8.0 (- 16.0, 30.0) 0.600
p value 0.496 0.821 0.739
Diastolic BP (mmHg)
Diuretics 18 78.5 (63.0 - 92.0) 75.5 (60.0 - 86.0) - 3.0 (- 18.0, 13.0) 0.138
ACE inhibitors 3 76.0 (74.0 - 88.0) 71.0 (70.0 - 77.0) - 4.0 (- 17.0, 1.0) 0.285
Beta-blockers 11 80.0 (64.0 - 94.0) 70.0 (60.0 - 93.0) - 4.0 (- 22.0, 8.0) 0.061
Calcium antagonist 19 80.0 (58.0 - 95.0) 74.0 (56.0 - 95.0) - 4.0 (- 26.0, 22.0) 0.227
Combination A 13 74.0 (67.0 - 90.0) 72.0 (60.0 - 89.0) - 5.0 (- 20.0, 14.0) 0.327
Combination B
§ 7 80.0 (65.0 - 90.0) 75.0 (65.0 - 80.0) - 1.0 (- 19.0, 15.0) 0.343
p value 0.943 0.932 0.964
BP, blood pressure; ACE, angiotensin-converting enzyme.
Data presented are medians (5th-95th percentiles).
*Wilcoxon signed rank test.
Kruskal-Wallis test.
A diuretic and another.
§Any combination of two or more antihypertensive medications except a diuretic.Terazosin Therapy and Hypertension
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an improvement appears to be shorter in Asian
men than in European men, which may be related
to the lower dose required to maintain an effective
blood level in Asian men. A dose-determining
study on terazosin in Japanese patients with
hypertension showed that 1 mg daily was
optimal.
9 However, since it has been reported that
terazosin acts on the central nervous system,
10,11
an increased dosage might additively block alpha-
1 receptors in the lumbosacral cord, increase the
threshold of bladder sensation, and thus improve
collecting disorders. Moreover, an increased dose
of terazosin might also block more alpha-1
receptors in the prostate and thus improve voiding.
In the HABIT trial, doxazosin was found to be
more effective, with an acceptable safety profile,
in concomitant hypertension and BPH, either as a
monotherapy or as an add-on therapy.
12 In this
study, BP at baseline and BP differences pre-/
post-treatment did not significantly differ between
the two groups. In addition, incidences of BP
outliers were similar in the two groups. Therefore,
a terazosin dose of 5 mg daily might not be too
high for hypertensive BPH patients. Furthermore,
as found by Lowe et al.,
13 our findings indicate
that terazosin can be safely used to treat patients
with LUTS regardless of blood pressure status
and the antihypertensive regimen used.
In the present study, there was no increase in
adverse events in patients with LUTS and con-
comitant hypertension. In the Hytrin Community
Assessment Trial of terazosin, BP related adverse
events (i.e., syncope, dizziness, hypotension, pos-
tural hypotension, vertigo) were experienced by
13.1% of men who were taking other anti-hyper-
tensives, compared with 15.2% for those who
were not.
14 A combined analysis of six placebo-
controlled trials involving 996 patients assessed
the safety and efficacy of terazosin for the treat-
ment of BPH and concluded that terazosin can be
administered safely to both normotensive and
hypertensive patients with BPH.
15 Moreover, a
recent study stressed that care should be taken
when first administering terazosin in a patient re-
ceiving the calcium antagonist verapamil, because
orthostatic hypotension occurred in six of 24
patients.
16 However, we did not encounter
orthostatic hypotension in our patients, although
the number of patients was small (n = 19). This
finding suggests that terazosin can be admini-
stered safely to hypertensive patients on a calcium
antagonist. Furthermore, results of an analysis of
adverse event data by a Veterans Affairs cooper-
ative study suggested that dizziness and asthenia
associated with alpha-1-adrenoceptor antagonists
may not be due to vascular events.
17
Our findings suggest that 5 mg terazosin is
effective and has an acceptable safety profile in
patients with LUTS with concomitant hyperten-
sion, and that terazosin (5 mg) may be safely
added to ongoing antihypertensive therapy in this
population. However, since this is a short-term
follow-up study and may be underpowered statis-
tically, a long-term follow-up and a larger-scale
study is needed. In addition, our results demon-
strate a need for a study designed to establish the
optimal dosage regimen in an Asian population in
order to ensure the safe and effective management
of LUTS.
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